nodes	percent_of_prediction	percent_of_DWPC	metapath
Gefitinib—Vandetanib—thyroid cancer	0.31	1	CrCtD
Gefitinib—lung cancer—thyroid cancer	0.183	1	CtDrD
Gefitinib—Afatinib—Vandetanib—thyroid cancer	0.0735	0.333	CrCrCtD
Gefitinib—Erlotinib—Vandetanib—thyroid cancer	0.0735	0.333	CrCrCtD
Gefitinib—Bosutinib—Vandetanib—thyroid cancer	0.0735	0.333	CrCrCtD
Gefitinib—ERBB3—Vandetanib—thyroid cancer	0.0236	0.106	CbGbCtD
Gefitinib—MKNK1—Vandetanib—thyroid cancer	0.0236	0.106	CbGbCtD
Gefitinib—IRAK4—Vandetanib—thyroid cancer	0.0236	0.106	CbGbCtD
Gefitinib—MKNK2—Sorafenib—thyroid cancer	0.0179	0.0802	CbGbCtD
Gefitinib—EPHA6—Vandetanib—thyroid cancer	0.0151	0.0675	CbGbCtD
Gefitinib—MKNK1—Sorafenib—thyroid cancer	0.0142	0.0637	CbGbCtD
Gefitinib—EGFR—Vandetanib—thyroid cancer	0.0135	0.0607	CbGbCtD
Gefitinib—STK10—Vandetanib—thyroid cancer	0.0135	0.0607	CbGbCtD
Gefitinib—MAP2K5—Vandetanib—thyroid cancer	0.0123	0.0552	CbGbCtD
Gefitinib—MAP3K19—Vandetanib—thyroid cancer	0.0113	0.0508	CbGbCtD
Gefitinib—HIPK4—Sorafenib—thyroid cancer	0.00908	0.0407	CbGbCtD
Gefitinib—EPHA6—Sorafenib—thyroid cancer	0.00908	0.0407	CbGbCtD
Gefitinib—STK10—Sorafenib—thyroid cancer	0.00816	0.0366	CbGbCtD
Gefitinib—MAP2K5—Sorafenib—thyroid cancer	0.00743	0.0333	CbGbCtD
Gefitinib—MAP3K19—Sorafenib—thyroid cancer	0.00683	0.0306	CbGbCtD
Gefitinib—ORM1—Vandetanib—thyroid cancer	0.00366	0.0164	CbGbCtD
Gefitinib—ABCG2—Vandetanib—thyroid cancer	0.00224	0.01	CbGbCtD
Gefitinib—ALB—Vandetanib—thyroid cancer	0.00154	0.00691	CbGbCtD
Gefitinib—ABCG2—Sorafenib—thyroid cancer	0.00135	0.00604	CbGbCtD
Gefitinib—ABCG2—Doxorubicin—thyroid cancer	0.000818	0.00367	CbGbCtD
Gefitinib—CYP3A5—Sorafenib—thyroid cancer	0.000747	0.00335	CbGbCtD
Gefitinib—CYP2C19—Sorafenib—thyroid cancer	0.000602	0.0027	CbGbCtD
Gefitinib—CYP2C9—Sorafenib—thyroid cancer	0.000501	0.00224	CbGbCtD
Gefitinib—Vandetanib—RET—thyroid cancer	0.000492	1	CrCbGaD
Gefitinib—ABCB1—Sorafenib—thyroid cancer	0.000486	0.00218	CbGbCtD
Gefitinib—CYP3A4—Vandetanib—thyroid cancer	0.000483	0.00217	CbGbCtD
Gefitinib—CYP2D6—Sorafenib—thyroid cancer	0.000458	0.00205	CbGbCtD
Gefitinib—SBK1—thyroid gland—thyroid cancer	0.000434	0.0402	CbGeAlD
Gefitinib—CSNK1E—saliva-secreting gland—thyroid cancer	0.000393	0.0364	CbGeAlD
Gefitinib—IRAK4—saliva-secreting gland—thyroid cancer	0.000387	0.0359	CbGeAlD
Gefitinib—SBK1—head—thyroid cancer	0.000385	0.0357	CbGeAlD
Gefitinib—ERBB3—saliva-secreting gland—thyroid cancer	0.000379	0.0351	CbGeAlD
Gefitinib—CHEK2—thyroid gland—thyroid cancer	0.000378	0.0351	CbGeAlD
Gefitinib—MKNK2—saliva-secreting gland—thyroid cancer	0.000361	0.0334	CbGeAlD
Gefitinib—CSNK1E—trachea—thyroid cancer	0.000303	0.0281	CbGeAlD
Gefitinib—EPHA6—head—thyroid cancer	0.000301	0.0279	CbGeAlD
Gefitinib—IRAK4—trachea—thyroid cancer	0.000298	0.0277	CbGeAlD
Gefitinib—ABCB1—Doxorubicin—thyroid cancer	0.000295	0.00132	CbGbCtD
Gefitinib—ERBB3—trachea—thyroid cancer	0.000293	0.0271	CbGeAlD
Gefitinib—CYP3A4—Sorafenib—thyroid cancer	0.000291	0.0013	CbGbCtD
Gefitinib—MKNK2—trachea—thyroid cancer	0.000278	0.0258	CbGeAlD
Gefitinib—CYP2D6—Doxorubicin—thyroid cancer	0.000278	0.00125	CbGbCtD
Gefitinib—MAP3K19—head—thyroid cancer	0.000274	0.0254	CbGeAlD
Gefitinib—SBK1—lymph node—thyroid cancer	0.00027	0.025	CbGeAlD
Gefitinib—MAP2K5—saliva-secreting gland—thyroid cancer	0.000262	0.0243	CbGeAlD
Gefitinib—EGFR—thyroid gland—thyroid cancer	0.000249	0.0231	CbGeAlD
Gefitinib—CSNK1E—thyroid gland—thyroid cancer	0.00024	0.0222	CbGeAlD
Gefitinib—IRAK4—thyroid gland—thyroid cancer	0.000236	0.0219	CbGeAlD
Gefitinib—CHEK2—lymph node—thyroid cancer	0.000235	0.0218	CbGeAlD
Gefitinib—CHEK2—Doxorubicin—Epirubicin—thyroid cancer	0.000233	0.519	CbGdCrCtD
Gefitinib—ERBB3—thyroid gland—thyroid cancer	0.000231	0.0214	CbGeAlD
Gefitinib—MKNK2—thyroid gland—thyroid cancer	0.00022	0.0204	CbGeAlD
Gefitinib—IRAK1—thyroid gland—thyroid cancer	0.00022	0.0204	CbGeAlD
Gefitinib—MKNK1—thyroid gland—thyroid cancer	0.000217	0.0201	CbGeAlD
Gefitinib—CHEK2—Epirubicin—Doxorubicin—thyroid cancer	0.000215	0.481	CbGdCrCtD
Gefitinib—CSNK1E—head—thyroid cancer	0.000213	0.0197	CbGeAlD
Gefitinib—IRAK4—head—thyroid cancer	0.000209	0.0194	CbGeAlD
Gefitinib—ERBB3—head—thyroid cancer	0.000205	0.019	CbGeAlD
Gefitinib—MAP2K5—trachea—thyroid cancer	0.000202	0.0187	CbGeAlD
Gefitinib—MKNK2—head—thyroid cancer	0.000195	0.0181	CbGeAlD
Gefitinib—MKNK1—head—thyroid cancer	0.000193	0.0179	CbGeAlD
Gefitinib—STK10—thyroid gland—thyroid cancer	0.000179	0.0166	CbGeAlD
Gefitinib—CYP3A4—Doxorubicin—thyroid cancer	0.000177	0.000792	CbGbCtD
Gefitinib—MAP2K5—thyroid gland—thyroid cancer	0.00016	0.0148	CbGeAlD
Gefitinib—STK10—head—thyroid cancer	0.000159	0.0147	CbGeAlD
Gefitinib—EGFR—lymph node—thyroid cancer	0.000155	0.0144	CbGeAlD
Gefitinib—CSNK1E—lymph node—thyroid cancer	0.000149	0.0138	CbGeAlD
Gefitinib—IRAK4—lymph node—thyroid cancer	0.000147	0.0136	CbGeAlD
Gefitinib—ERBB3—lymph node—thyroid cancer	0.000144	0.0133	CbGeAlD
Gefitinib—MAP2K5—head—thyroid cancer	0.000142	0.0131	CbGeAlD
Gefitinib—IRAK1—lymph node—thyroid cancer	0.000137	0.0127	CbGeAlD
Gefitinib—MKNK2—lymph node—thyroid cancer	0.000137	0.0127	CbGeAlD
Gefitinib—MKNK1—lymph node—thyroid cancer	0.000135	0.0125	CbGeAlD
Gefitinib—ABCG2—saliva-secreting gland—thyroid cancer	0.000127	0.0118	CbGeAlD
Gefitinib—Arrhythmia—Vandetanib—thyroid cancer	0.000117	0.0042	CcSEcCtD
Gefitinib—Hypokalaemia—Sorafenib—thyroid cancer	0.000116	0.00417	CcSEcCtD
Gefitinib—Vesiculobullous rash—Epirubicin—thyroid cancer	0.000116	0.00416	CcSEcCtD
Gefitinib—Alopecia—Vandetanib—thyroid cancer	0.000116	0.00415	CcSEcCtD
Gefitinib—Toxic epidermal necrolysis—Sorafenib—thyroid cancer	0.000115	0.00413	CcSEcCtD
Gefitinib—Aspartate aminotransferase increased—Sorafenib—thyroid cancer	0.000115	0.00413	CcSEcCtD
Gefitinib—Anorectal disorder—Doxorubicin—thyroid cancer	0.000115	0.00411	CcSEcCtD
Gefitinib—Malnutrition—Vandetanib—thyroid cancer	0.000114	0.00409	CcSEcCtD
Gefitinib—Alanine aminotransferase increased—Sorafenib—thyroid cancer	0.000113	0.00404	CcSEcCtD
Gefitinib—Gastric ulcer—Epirubicin—thyroid cancer	0.000112	0.00402	CcSEcCtD
Gefitinib—STK10—lymph node—thyroid cancer	0.000111	0.0103	CbGeAlD
Gefitinib—Pancreatitis—Sorafenib—thyroid cancer	0.000108	0.00388	CcSEcCtD
Gefitinib—Febrile neutropenia—Epirubicin—thyroid cancer	0.000108	0.00388	CcSEcCtD
Gefitinib—Vesiculobullous rash—Doxorubicin—thyroid cancer	0.000108	0.00385	CcSEcCtD
Gefitinib—Eruption—Epirubicin—thyroid cancer	0.000106	0.00379	CcSEcCtD
Gefitinib—Gastric ulcer—Doxorubicin—thyroid cancer	0.000104	0.00372	CcSEcCtD
Gefitinib—Hypomagnesaemia—Epirubicin—thyroid cancer	0.000103	0.00367	CcSEcCtD
Gefitinib—Keratitis—Epirubicin—thyroid cancer	0.0001	0.0036	CcSEcCtD
Gefitinib—Nail disorder—Epirubicin—thyroid cancer	0.0001	0.0036	CcSEcCtD
Gefitinib—Febrile neutropenia—Doxorubicin—thyroid cancer	0.0001	0.00359	CcSEcCtD
Gefitinib—Weight decreased—Sorafenib—thyroid cancer	0.0001	0.00358	CcSEcCtD
Gefitinib—Cough—Vandetanib—thyroid cancer	9.97e-05	0.00357	CcSEcCtD
Gefitinib—MAP2K5—lymph node—thyroid cancer	9.93e-05	0.0092	CbGeAlD
Gefitinib—Pneumonia—Sorafenib—thyroid cancer	9.92e-05	0.00355	CcSEcCtD
Gefitinib—Infestation NOS—Sorafenib—thyroid cancer	9.86e-05	0.00353	CcSEcCtD
Gefitinib—Infestation—Sorafenib—thyroid cancer	9.86e-05	0.00353	CcSEcCtD
Gefitinib—Eruption—Doxorubicin—thyroid cancer	9.8e-05	0.00351	CcSEcCtD
Gefitinib—Stevens-Johnson syndrome—Sorafenib—thyroid cancer	9.78e-05	0.0035	CcSEcCtD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Vandetanib—thyroid cancer	9.66e-05	0.00346	CcSEcCtD
Gefitinib—Stomatitis—Sorafenib—thyroid cancer	9.62e-05	0.00344	CcSEcCtD
Gefitinib—Seborrhoeic dermatitis—Epirubicin—thyroid cancer	9.56e-05	0.00342	CcSEcCtD
Gefitinib—Dry mouth—Vandetanib—thyroid cancer	9.51e-05	0.00341	CcSEcCtD
Gefitinib—Hypomagnesaemia—Doxorubicin—thyroid cancer	9.49e-05	0.0034	CcSEcCtD
Gefitinib—CYP1A1—trachea—thyroid cancer	9.33e-05	0.00865	CbGeAlD
Gefitinib—Hepatobiliary disease—Sorafenib—thyroid cancer	9.33e-05	0.00334	CcSEcCtD
Gefitinib—Epistaxis—Sorafenib—thyroid cancer	9.3e-05	0.00333	CcSEcCtD
Gefitinib—Nail disorder—Doxorubicin—thyroid cancer	9.3e-05	0.00333	CcSEcCtD
Gefitinib—Keratitis—Doxorubicin—thyroid cancer	9.3e-05	0.00333	CcSEcCtD
Gefitinib—Infection—Vandetanib—thyroid cancer	9.27e-05	0.00332	CcSEcCtD
Gefitinib—Nervous system disorder—Vandetanib—thyroid cancer	9.15e-05	0.00327	CcSEcCtD
Gefitinib—Thrombocytopenia—Vandetanib—thyroid cancer	9.13e-05	0.00327	CcSEcCtD
Gefitinib—Skin disorder—Vandetanib—thyroid cancer	9.06e-05	0.00324	CcSEcCtD
Gefitinib—Haemoglobin—Sorafenib—thyroid cancer	8.9e-05	0.00319	CcSEcCtD
Gefitinib—Haemorrhage—Sorafenib—thyroid cancer	8.86e-05	0.00317	CcSEcCtD
Gefitinib—Seborrhoeic dermatitis—Doxorubicin—thyroid cancer	8.85e-05	0.00317	CcSEcCtD
Gefitinib—Haemoptysis—Epirubicin—thyroid cancer	8.8e-05	0.00315	CcSEcCtD
Gefitinib—Urinary tract disorder—Sorafenib—thyroid cancer	8.75e-05	0.00313	CcSEcCtD
Gefitinib—Urethral disorder—Sorafenib—thyroid cancer	8.68e-05	0.00311	CcSEcCtD
Gefitinib—Pleural effusion—Epirubicin—thyroid cancer	8.51e-05	0.00305	CcSEcCtD
Gefitinib—Amblyopia—Epirubicin—thyroid cancer	8.44e-05	0.00302	CcSEcCtD
Gefitinib—Erythema multiforme—Sorafenib—thyroid cancer	8.37e-05	0.003	CcSEcCtD
Gefitinib—Dyspnoea—Vandetanib—thyroid cancer	8.31e-05	0.00298	CcSEcCtD
Gefitinib—Cardiac disorder—Sorafenib—thyroid cancer	8.22e-05	0.00294	CcSEcCtD
Gefitinib—Rash pustular—Epirubicin—thyroid cancer	8.17e-05	0.00293	CcSEcCtD
Gefitinib—Haemoptysis—Doxorubicin—thyroid cancer	8.15e-05	0.00292	CcSEcCtD
Gefitinib—Decreased appetite—Vandetanib—thyroid cancer	8.11e-05	0.0029	CcSEcCtD
Gefitinib—ORM1—lymph node—thyroid cancer	8.06e-05	0.00747	CbGeAlD
Gefitinib—Gastrointestinal disorder—Vandetanib—thyroid cancer	8.05e-05	0.00288	CcSEcCtD
Gefitinib—Fatigue—Vandetanib—thyroid cancer	8.04e-05	0.00288	CcSEcCtD
Gefitinib—Angiopathy—Sorafenib—thyroid cancer	8.03e-05	0.00288	CcSEcCtD
Gefitinib—Mediastinal disorder—Sorafenib—thyroid cancer	7.98e-05	0.00286	CcSEcCtD
Gefitinib—Pain—Vandetanib—thyroid cancer	7.98e-05	0.00286	CcSEcCtD
Gefitinib—Constipation—Vandetanib—thyroid cancer	7.98e-05	0.00286	CcSEcCtD
Gefitinib—Arrhythmia—Sorafenib—thyroid cancer	7.91e-05	0.00283	CcSEcCtD
Gefitinib—Pleural effusion—Doxorubicin—thyroid cancer	7.87e-05	0.00282	CcSEcCtD
Gefitinib—Alopecia—Sorafenib—thyroid cancer	7.83e-05	0.0028	CcSEcCtD
Gefitinib—Amblyopia—Doxorubicin—thyroid cancer	7.81e-05	0.0028	CcSEcCtD
Gefitinib—ABCG2—thyroid gland—thyroid cancer	7.77e-05	0.0072	CbGeAlD
Gefitinib—Malnutrition—Sorafenib—thyroid cancer	7.71e-05	0.00276	CcSEcCtD
Gefitinib—Gastrointestinal pain—Vandetanib—thyroid cancer	7.63e-05	0.00273	CcSEcCtD
Gefitinib—Rash pustular—Doxorubicin—thyroid cancer	7.56e-05	0.00271	CcSEcCtD
Gefitinib—CYP1A1—thyroid gland—thyroid cancer	7.38e-05	0.00684	CbGeAlD
Gefitinib—Body temperature increased—Vandetanib—thyroid cancer	7.37e-05	0.00264	CcSEcCtD
Gefitinib—Abdominal pain—Vandetanib—thyroid cancer	7.37e-05	0.00264	CcSEcCtD
Gefitinib—Anaemia—Sorafenib—thyroid cancer	7.12e-05	0.00255	CcSEcCtD
Gefitinib—ALB—lymph node—thyroid cancer	7.07e-05	0.00655	CbGeAlD
Gefitinib—Angioedema—Sorafenib—thyroid cancer	7.04e-05	0.00252	CcSEcCtD
Gefitinib—Ulcer—Epirubicin—thyroid cancer	6.89e-05	0.00247	CcSEcCtD
Gefitinib—Cough—Sorafenib—thyroid cancer	6.73e-05	0.00241	CcSEcCtD
Gefitinib—Asthenia—Vandetanib—thyroid cancer	6.69e-05	0.0024	CcSEcCtD
Gefitinib—Pruritus—Vandetanib—thyroid cancer	6.6e-05	0.00236	CcSEcCtD
Gefitinib—CYP1A1—head—thyroid cancer	6.55e-05	0.00607	CbGeAlD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—thyroid cancer	6.52e-05	0.00233	CcSEcCtD
Gefitinib—Dry mouth—Sorafenib—thyroid cancer	6.42e-05	0.0023	CcSEcCtD
Gefitinib—Diarrhoea—Vandetanib—thyroid cancer	6.38e-05	0.00228	CcSEcCtD
Gefitinib—Ulcer—Doxorubicin—thyroid cancer	6.38e-05	0.00228	CcSEcCtD
Gefitinib—Melaena—Epirubicin—thyroid cancer	6.37e-05	0.00228	CcSEcCtD
Gefitinib—Cystitis noninfective—Epirubicin—thyroid cancer	6.37e-05	0.00228	CcSEcCtD
Gefitinib—Cystitis—Epirubicin—thyroid cancer	6.29e-05	0.00225	CcSEcCtD
Gefitinib—Infection—Sorafenib—thyroid cancer	6.25e-05	0.00224	CcSEcCtD
Gefitinib—Shock—Sorafenib—thyroid cancer	6.19e-05	0.00222	CcSEcCtD
Gefitinib—Nervous system disorder—Sorafenib—thyroid cancer	6.17e-05	0.00221	CcSEcCtD
Gefitinib—Thrombocytopenia—Sorafenib—thyroid cancer	6.16e-05	0.00221	CcSEcCtD
Gefitinib—Skin disorder—Sorafenib—thyroid cancer	6.11e-05	0.00219	CcSEcCtD
Gefitinib—Dry eye—Epirubicin—thyroid cancer	6.02e-05	0.00216	CcSEcCtD
Gefitinib—Anorexia—Sorafenib—thyroid cancer	6e-05	0.00215	CcSEcCtD
Gefitinib—Vomiting—Vandetanib—thyroid cancer	5.93e-05	0.00212	CcSEcCtD
Gefitinib—Bladder pain—Epirubicin—thyroid cancer	5.89e-05	0.00211	CcSEcCtD
Gefitinib—Mouth ulceration—Epirubicin—thyroid cancer	5.89e-05	0.00211	CcSEcCtD
Gefitinib—Melaena—Doxorubicin—thyroid cancer	5.89e-05	0.00211	CcSEcCtD
Gefitinib—Cystitis noninfective—Doxorubicin—thyroid cancer	5.89e-05	0.00211	CcSEcCtD
Gefitinib—Rash—Vandetanib—thyroid cancer	5.88e-05	0.00211	CcSEcCtD
Gefitinib—Dermatitis—Vandetanib—thyroid cancer	5.88e-05	0.0021	CcSEcCtD
Gefitinib—Cystitis—Doxorubicin—thyroid cancer	5.82e-05	0.00208	CcSEcCtD
Gefitinib—Dyspnoea—Sorafenib—thyroid cancer	5.61e-05	0.00201	CcSEcCtD
Gefitinib—Dry eye—Doxorubicin—thyroid cancer	5.57e-05	0.00199	CcSEcCtD
Gefitinib—Nausea—Vandetanib—thyroid cancer	5.54e-05	0.00198	CcSEcCtD
Gefitinib—Decreased appetite—Sorafenib—thyroid cancer	5.47e-05	0.00196	CcSEcCtD
Gefitinib—Thrombophlebitis—Epirubicin—thyroid cancer	5.46e-05	0.00196	CcSEcCtD
Gefitinib—Bladder pain—Doxorubicin—thyroid cancer	5.45e-05	0.00195	CcSEcCtD
Gefitinib—Mouth ulceration—Doxorubicin—thyroid cancer	5.45e-05	0.00195	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Sorafenib—thyroid cancer	5.43e-05	0.00194	CcSEcCtD
Gefitinib—Fatigue—Sorafenib—thyroid cancer	5.42e-05	0.00194	CcSEcCtD
Gefitinib—Constipation—Sorafenib—thyroid cancer	5.38e-05	0.00193	CcSEcCtD
Gefitinib—Pain—Sorafenib—thyroid cancer	5.38e-05	0.00193	CcSEcCtD
Gefitinib—Hepatic failure—Epirubicin—thyroid cancer	5.26e-05	0.00188	CcSEcCtD
Gefitinib—Eye pain—Epirubicin—thyroid cancer	5.24e-05	0.00188	CcSEcCtD
Gefitinib—Gastrointestinal pain—Sorafenib—thyroid cancer	5.14e-05	0.00184	CcSEcCtD
Gefitinib—Thrombophlebitis—Doxorubicin—thyroid cancer	5.06e-05	0.00181	CcSEcCtD
Gefitinib—Dermatitis exfoliative—Epirubicin—thyroid cancer	5.01e-05	0.0018	CcSEcCtD
Gefitinib—Urticaria—Sorafenib—thyroid cancer	5e-05	0.00179	CcSEcCtD
Gefitinib—Abdominal pain—Sorafenib—thyroid cancer	4.97e-05	0.00178	CcSEcCtD
Gefitinib—Body temperature increased—Sorafenib—thyroid cancer	4.97e-05	0.00178	CcSEcCtD
Gefitinib—Dermatitis bullous—Epirubicin—thyroid cancer	4.95e-05	0.00177	CcSEcCtD
Gefitinib—Hepatic failure—Doxorubicin—thyroid cancer	4.87e-05	0.00174	CcSEcCtD
Gefitinib—Eye pain—Doxorubicin—thyroid cancer	4.85e-05	0.00174	CcSEcCtD
Gefitinib—ABCB1—trachea—thyroid cancer	4.85e-05	0.00449	CbGeAlD
Gefitinib—ABCG2—lymph node—thyroid cancer	4.83e-05	0.00448	CbGeAlD
Gefitinib—CYP2D6—head—thyroid cancer	4.73e-05	0.00438	CbGeAlD
Gefitinib—Dermatitis exfoliative—Doxorubicin—thyroid cancer	4.64e-05	0.00166	CcSEcCtD
Gefitinib—Hypersensitivity—Sorafenib—thyroid cancer	4.64e-05	0.00166	CcSEcCtD
Gefitinib—CYP1A1—lymph node—thyroid cancer	4.58e-05	0.00425	CbGeAlD
Gefitinib—Dermatitis bullous—Doxorubicin—thyroid cancer	4.58e-05	0.00164	CcSEcCtD
Gefitinib—Asthenia—Sorafenib—thyroid cancer	4.51e-05	0.00162	CcSEcCtD
Gefitinib—Pruritus—Sorafenib—thyroid cancer	4.45e-05	0.00159	CcSEcCtD
Gefitinib—Dehydration—Epirubicin—thyroid cancer	4.4e-05	0.00158	CcSEcCtD
Gefitinib—Dry skin—Epirubicin—thyroid cancer	4.34e-05	0.00155	CcSEcCtD
Gefitinib—Hypokalaemia—Epirubicin—thyroid cancer	4.31e-05	0.00154	CcSEcCtD
Gefitinib—Diarrhoea—Sorafenib—thyroid cancer	4.3e-05	0.00154	CcSEcCtD
Gefitinib—Toxic epidermal necrolysis—Epirubicin—thyroid cancer	4.26e-05	0.00153	CcSEcCtD
Gefitinib—Aspartate aminotransferase increased—Epirubicin—thyroid cancer	4.26e-05	0.00153	CcSEcCtD
Gefitinib—Alanine aminotransferase increased—Epirubicin—thyroid cancer	4.17e-05	0.00149	CcSEcCtD
Gefitinib—Dehydration—Doxorubicin—thyroid cancer	4.07e-05	0.00146	CcSEcCtD
Gefitinib—Dry skin—Doxorubicin—thyroid cancer	4.01e-05	0.00144	CcSEcCtD
Gefitinib—Pancreatitis—Epirubicin—thyroid cancer	4.01e-05	0.00144	CcSEcCtD
Gefitinib—Vomiting—Sorafenib—thyroid cancer	4e-05	0.00143	CcSEcCtD
Gefitinib—Hypokalaemia—Doxorubicin—thyroid cancer	3.98e-05	0.00143	CcSEcCtD
Gefitinib—Rash—Sorafenib—thyroid cancer	3.97e-05	0.00142	CcSEcCtD
Gefitinib—Dermatitis—Sorafenib—thyroid cancer	3.96e-05	0.00142	CcSEcCtD
Gefitinib—Aspartate aminotransferase increased—Doxorubicin—thyroid cancer	3.94e-05	0.00141	CcSEcCtD
Gefitinib—Toxic epidermal necrolysis—Doxorubicin—thyroid cancer	3.94e-05	0.00141	CcSEcCtD
Gefitinib—Alanine aminotransferase increased—Doxorubicin—thyroid cancer	3.86e-05	0.00138	CcSEcCtD
Gefitinib—ABCB1—thyroid gland—thyroid cancer	3.83e-05	0.00355	CbGeAlD
Gefitinib—Nausea—Sorafenib—thyroid cancer	3.74e-05	0.00134	CcSEcCtD
Gefitinib—Pancreatitis—Doxorubicin—thyroid cancer	3.71e-05	0.00133	CcSEcCtD
Gefitinib—Weight decreased—Epirubicin—thyroid cancer	3.7e-05	0.00132	CcSEcCtD
Gefitinib—Pneumonia—Epirubicin—thyroid cancer	3.67e-05	0.00131	CcSEcCtD
Gefitinib—Infestation NOS—Epirubicin—thyroid cancer	3.65e-05	0.00131	CcSEcCtD
Gefitinib—Infestation—Epirubicin—thyroid cancer	3.65e-05	0.00131	CcSEcCtD
Gefitinib—Stevens-Johnson syndrome—Epirubicin—thyroid cancer	3.61e-05	0.00129	CcSEcCtD
Gefitinib—Stomatitis—Epirubicin—thyroid cancer	3.55e-05	0.00127	CcSEcCtD
Gefitinib—Conjunctivitis—Epirubicin—thyroid cancer	3.54e-05	0.00127	CcSEcCtD
Gefitinib—Haematuria—Epirubicin—thyroid cancer	3.48e-05	0.00124	CcSEcCtD
Gefitinib—Hepatobiliary disease—Epirubicin—thyroid cancer	3.45e-05	0.00123	CcSEcCtD
Gefitinib—Epistaxis—Epirubicin—thyroid cancer	3.44e-05	0.00123	CcSEcCtD
Gefitinib—Weight decreased—Doxorubicin—thyroid cancer	3.42e-05	0.00123	CcSEcCtD
Gefitinib—ABCB1—head—thyroid cancer	3.4e-05	0.00315	CbGeAlD
Gefitinib—Pneumonia—Doxorubicin—thyroid cancer	3.39e-05	0.00121	CcSEcCtD
Gefitinib—Infestation NOS—Doxorubicin—thyroid cancer	3.37e-05	0.00121	CcSEcCtD
Gefitinib—Infestation—Doxorubicin—thyroid cancer	3.37e-05	0.00121	CcSEcCtD
Gefitinib—Stevens-Johnson syndrome—Doxorubicin—thyroid cancer	3.34e-05	0.0012	CcSEcCtD
Gefitinib—Haemoglobin—Epirubicin—thyroid cancer	3.29e-05	0.00118	CcSEcCtD
Gefitinib—Stomatitis—Doxorubicin—thyroid cancer	3.29e-05	0.00118	CcSEcCtD
Gefitinib—Conjunctivitis—Doxorubicin—thyroid cancer	3.28e-05	0.00117	CcSEcCtD
Gefitinib—Hepatitis—Epirubicin—thyroid cancer	3.27e-05	0.00117	CcSEcCtD
Gefitinib—Haemorrhage—Epirubicin—thyroid cancer	3.27e-05	0.00117	CcSEcCtD
Gefitinib—Urinary tract disorder—Epirubicin—thyroid cancer	3.23e-05	0.00116	CcSEcCtD
Gefitinib—Oedema peripheral—Epirubicin—thyroid cancer	3.22e-05	0.00115	CcSEcCtD
Gefitinib—Haematuria—Doxorubicin—thyroid cancer	3.22e-05	0.00115	CcSEcCtD
Gefitinib—Urethral disorder—Epirubicin—thyroid cancer	3.21e-05	0.00115	CcSEcCtD
Gefitinib—Hepatobiliary disease—Doxorubicin—thyroid cancer	3.19e-05	0.00114	CcSEcCtD
Gefitinib—Epistaxis—Doxorubicin—thyroid cancer	3.18e-05	0.00114	CcSEcCtD
Gefitinib—Erythema multiforme—Epirubicin—thyroid cancer	3.09e-05	0.00111	CcSEcCtD
Gefitinib—Eye disorder—Epirubicin—thyroid cancer	3.06e-05	0.0011	CcSEcCtD
Gefitinib—Haemoglobin—Doxorubicin—thyroid cancer	3.04e-05	0.00109	CcSEcCtD
Gefitinib—Cardiac disorder—Epirubicin—thyroid cancer	3.04e-05	0.00109	CcSEcCtD
Gefitinib—Hepatitis—Doxorubicin—thyroid cancer	3.03e-05	0.00108	CcSEcCtD
Gefitinib—Haemorrhage—Doxorubicin—thyroid cancer	3.03e-05	0.00108	CcSEcCtD
Gefitinib—Urinary tract disorder—Doxorubicin—thyroid cancer	2.99e-05	0.00107	CcSEcCtD
Gefitinib—Oedema peripheral—Doxorubicin—thyroid cancer	2.98e-05	0.00107	CcSEcCtD
Gefitinib—Angiopathy—Epirubicin—thyroid cancer	2.97e-05	0.00106	CcSEcCtD
Gefitinib—Urethral disorder—Doxorubicin—thyroid cancer	2.97e-05	0.00106	CcSEcCtD
Gefitinib—Mediastinal disorder—Epirubicin—thyroid cancer	2.95e-05	0.00106	CcSEcCtD
Gefitinib—Arrhythmia—Epirubicin—thyroid cancer	2.92e-05	0.00105	CcSEcCtD
Gefitinib—Alopecia—Epirubicin—thyroid cancer	2.89e-05	0.00104	CcSEcCtD
Gefitinib—Erythema multiforme—Doxorubicin—thyroid cancer	2.86e-05	0.00103	CcSEcCtD
Gefitinib—Malnutrition—Epirubicin—thyroid cancer	2.85e-05	0.00102	CcSEcCtD
Gefitinib—Eye disorder—Doxorubicin—thyroid cancer	2.83e-05	0.00101	CcSEcCtD
Gefitinib—Cardiac disorder—Doxorubicin—thyroid cancer	2.81e-05	0.00101	CcSEcCtD
Gefitinib—Angiopathy—Doxorubicin—thyroid cancer	2.75e-05	0.000984	CcSEcCtD
Gefitinib—Mediastinal disorder—Doxorubicin—thyroid cancer	2.73e-05	0.000977	CcSEcCtD
Gefitinib—Arrhythmia—Doxorubicin—thyroid cancer	2.71e-05	0.000969	CcSEcCtD
Gefitinib—Alopecia—Doxorubicin—thyroid cancer	2.68e-05	0.000958	CcSEcCtD
Gefitinib—Malnutrition—Doxorubicin—thyroid cancer	2.64e-05	0.000944	CcSEcCtD
Gefitinib—Anaemia—Epirubicin—thyroid cancer	2.63e-05	0.000943	CcSEcCtD
Gefitinib—Malaise—Epirubicin—thyroid cancer	2.57e-05	0.00092	CcSEcCtD
Gefitinib—Cough—Epirubicin—thyroid cancer	2.49e-05	0.00089	CcSEcCtD
Gefitinib—Anaemia—Doxorubicin—thyroid cancer	2.44e-05	0.000872	CcSEcCtD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	2.41e-05	0.000862	CcSEcCtD
Gefitinib—ABCB1—lymph node—thyroid cancer	2.38e-05	0.00221	CbGeAlD
Gefitinib—Malaise—Doxorubicin—thyroid cancer	2.38e-05	0.000851	CcSEcCtD
Gefitinib—Dry mouth—Epirubicin—thyroid cancer	2.37e-05	0.000849	CcSEcCtD
Gefitinib—Infection—Epirubicin—thyroid cancer	2.31e-05	0.000827	CcSEcCtD
Gefitinib—Cough—Doxorubicin—thyroid cancer	2.3e-05	0.000824	CcSEcCtD
Gefitinib—Shock—Epirubicin—thyroid cancer	2.29e-05	0.000819	CcSEcCtD
Gefitinib—Nervous system disorder—Epirubicin—thyroid cancer	2.28e-05	0.000816	CcSEcCtD
Gefitinib—Thrombocytopenia—Epirubicin—thyroid cancer	2.28e-05	0.000815	CcSEcCtD
Gefitinib—Skin disorder—Epirubicin—thyroid cancer	2.26e-05	0.000809	CcSEcCtD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	2.23e-05	0.000798	CcSEcCtD
Gefitinib—Anorexia—Epirubicin—thyroid cancer	2.22e-05	0.000794	CcSEcCtD
Gefitinib—Dry mouth—Doxorubicin—thyroid cancer	2.19e-05	0.000786	CcSEcCtD
Gefitinib—Hypotension—Epirubicin—thyroid cancer	2.17e-05	0.000778	CcSEcCtD
Gefitinib—Infection—Doxorubicin—thyroid cancer	2.14e-05	0.000765	CcSEcCtD
Gefitinib—Shock—Doxorubicin—thyroid cancer	2.12e-05	0.000758	CcSEcCtD
Gefitinib—Nervous system disorder—Doxorubicin—thyroid cancer	2.11e-05	0.000755	CcSEcCtD
Gefitinib—Thrombocytopenia—Doxorubicin—thyroid cancer	2.11e-05	0.000754	CcSEcCtD
Gefitinib—Skin disorder—Doxorubicin—thyroid cancer	2.09e-05	0.000748	CcSEcCtD
Gefitinib—Dyspnoea—Epirubicin—thyroid cancer	2.07e-05	0.000742	CcSEcCtD
Gefitinib—Anorexia—Doxorubicin—thyroid cancer	2.05e-05	0.000734	CcSEcCtD
Gefitinib—Decreased appetite—Epirubicin—thyroid cancer	2.02e-05	0.000724	CcSEcCtD
Gefitinib—Hypotension—Doxorubicin—thyroid cancer	2.01e-05	0.00072	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Epirubicin—thyroid cancer	2.01e-05	0.000719	CcSEcCtD
Gefitinib—Fatigue—Epirubicin—thyroid cancer	2e-05	0.000718	CcSEcCtD
Gefitinib—Pain—Epirubicin—thyroid cancer	1.99e-05	0.000712	CcSEcCtD
Gefitinib—Constipation—Epirubicin—thyroid cancer	1.99e-05	0.000712	CcSEcCtD
Gefitinib—Dyspnoea—Doxorubicin—thyroid cancer	1.92e-05	0.000687	CcSEcCtD
Gefitinib—Gastrointestinal pain—Epirubicin—thyroid cancer	1.9e-05	0.000681	CcSEcCtD
Gefitinib—Decreased appetite—Doxorubicin—thyroid cancer	1.87e-05	0.00067	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Doxorubicin—thyroid cancer	1.86e-05	0.000665	CcSEcCtD
Gefitinib—Fatigue—Doxorubicin—thyroid cancer	1.85e-05	0.000664	CcSEcCtD
Gefitinib—Urticaria—Epirubicin—thyroid cancer	1.85e-05	0.000661	CcSEcCtD
Gefitinib—Constipation—Doxorubicin—thyroid cancer	1.84e-05	0.000659	CcSEcCtD
Gefitinib—Pain—Doxorubicin—thyroid cancer	1.84e-05	0.000659	CcSEcCtD
Gefitinib—Abdominal pain—Epirubicin—thyroid cancer	1.84e-05	0.000658	CcSEcCtD
Gefitinib—Body temperature increased—Epirubicin—thyroid cancer	1.84e-05	0.000658	CcSEcCtD
Gefitinib—Gastrointestinal pain—Doxorubicin—thyroid cancer	1.76e-05	0.00063	CcSEcCtD
Gefitinib—Hypersensitivity—Epirubicin—thyroid cancer	1.71e-05	0.000613	CcSEcCtD
Gefitinib—Urticaria—Doxorubicin—thyroid cancer	1.71e-05	0.000612	CcSEcCtD
Gefitinib—Body temperature increased—Doxorubicin—thyroid cancer	1.7e-05	0.000609	CcSEcCtD
Gefitinib—Abdominal pain—Doxorubicin—thyroid cancer	1.7e-05	0.000609	CcSEcCtD
Gefitinib—Asthenia—Epirubicin—thyroid cancer	1.67e-05	0.000597	CcSEcCtD
Gefitinib—Pruritus—Epirubicin—thyroid cancer	1.64e-05	0.000589	CcSEcCtD
Gefitinib—Diarrhoea—Epirubicin—thyroid cancer	1.59e-05	0.00057	CcSEcCtD
Gefitinib—Hypersensitivity—Doxorubicin—thyroid cancer	1.59e-05	0.000568	CcSEcCtD
Gefitinib—Asthenia—Doxorubicin—thyroid cancer	1.54e-05	0.000553	CcSEcCtD
Gefitinib—Pruritus—Doxorubicin—thyroid cancer	1.52e-05	0.000545	CcSEcCtD
Gefitinib—Vomiting—Epirubicin—thyroid cancer	1.48e-05	0.000529	CcSEcCtD
Gefitinib—Diarrhoea—Doxorubicin—thyroid cancer	1.47e-05	0.000527	CcSEcCtD
Gefitinib—Rash—Epirubicin—thyroid cancer	1.47e-05	0.000525	CcSEcCtD
Gefitinib—Dermatitis—Epirubicin—thyroid cancer	1.46e-05	0.000524	CcSEcCtD
Gefitinib—Nausea—Epirubicin—thyroid cancer	1.38e-05	0.000495	CcSEcCtD
Gefitinib—Vomiting—Doxorubicin—thyroid cancer	1.37e-05	0.00049	CcSEcCtD
Gefitinib—Rash—Doxorubicin—thyroid cancer	1.36e-05	0.000486	CcSEcCtD
Gefitinib—Dermatitis—Doxorubicin—thyroid cancer	1.36e-05	0.000485	CcSEcCtD
Gefitinib—Nausea—Doxorubicin—thyroid cancer	1.28e-05	0.000458	CcSEcCtD
Gefitinib—EGFR—B Cell Activation—AKT1—thyroid cancer	3.31e-06	0.000139	CbGpPWpGaD
Gefitinib—ERBB3—Disease—BRAF—thyroid cancer	3.31e-06	0.000139	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—HPGD—thyroid cancer	3.3e-06	0.000139	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—PRKAR1A—thyroid cancer	3.28e-06	0.000138	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—HPGD—thyroid cancer	3.28e-06	0.000138	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—NRG1—thyroid cancer	3.26e-06	0.000137	CbGpPWpGaD
Gefitinib—EGFR—Signaling by NGF—KRAS—thyroid cancer	3.25e-06	0.000137	CbGpPWpGaD
Gefitinib—ALB—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	3.25e-06	0.000137	CbGpPWpGaD
Gefitinib—EGFR—Disease—CDK1—thyroid cancer	3.23e-06	0.000136	CbGpPWpGaD
Gefitinib—IRAK1—Innate Immune System—NRAS—thyroid cancer	3.22e-06	0.000136	CbGpPWpGaD
Gefitinib—ABCB1—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	3.22e-06	0.000136	CbGpPWpGaD
Gefitinib—ERBB3—Adaptive Immune System—KRAS—thyroid cancer	3.2e-06	0.000135	CbGpPWpGaD
Gefitinib—EGFR—NGF signalling via TRKA from the plasma membrane—AKT1—thyroid cancer	3.17e-06	0.000133	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—PTEN—thyroid cancer	3.17e-06	0.000133	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—MEN1—thyroid cancer	3.14e-06	0.000132	CbGpPWpGaD
Gefitinib—IRAK4—Innate Immune System—AKT1—thyroid cancer	3.13e-06	0.000132	CbGpPWpGaD
Gefitinib—ALB—Transmembrane transport of small molecules—RXRA—thyroid cancer	3.09e-06	0.00013	CbGpPWpGaD
Gefitinib—CSNK1E—Disease—PTEN—thyroid cancer	3.06e-06	0.000129	CbGpPWpGaD
Gefitinib—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—thyroid cancer	3.06e-06	0.000129	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—BRAF—thyroid cancer	3.04e-06	0.000128	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—TERT—thyroid cancer	3.04e-06	0.000128	CbGpPWpGaD
Gefitinib—MKNK1—Disease—KRAS—thyroid cancer	3.02e-06	0.000127	CbGpPWpGaD
Gefitinib—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—thyroid cancer	2.95e-06	0.000124	CbGpPWpGaD
Gefitinib—EGFR—Axon guidance—KRAS—thyroid cancer	2.94e-06	0.000124	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—TERT—thyroid cancer	2.93e-06	0.000123	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	2.91e-06	0.000123	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—HIF1A—thyroid cancer	2.9e-06	0.000122	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—CCND1—thyroid cancer	2.86e-06	0.00012	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—NDUFA13—thyroid cancer	2.85e-06	0.00012	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—PTCH1—thyroid cancer	2.84e-06	0.000119	CbGpPWpGaD
Gefitinib—ERBB3—Innate Immune System—HRAS—thyroid cancer	2.83e-06	0.000119	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—NRAS—thyroid cancer	2.83e-06	0.000119	CbGpPWpGaD
Gefitinib—EGFR—Immune System—NRG1—thyroid cancer	2.81e-06	0.000118	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—HIF1A—thyroid cancer	2.8e-06	0.000118	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—SLC5A5—thyroid cancer	2.79e-06	0.000117	CbGpPWpGaD
Gefitinib—IRAK1—Innate Immune System—KRAS—thyroid cancer	2.77e-06	0.000117	CbGpPWpGaD
Gefitinib—EGFR—Signaling by NGF—HRAS—thyroid cancer	2.76e-06	0.000116	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—PTEN—thyroid cancer	2.76e-06	0.000116	CbGpPWpGaD
Gefitinib—CSNK1E—Disease—NRAS—thyroid cancer	2.73e-06	0.000115	CbGpPWpGaD
Gefitinib—ERBB3—Adaptive Immune System—HRAS—thyroid cancer	2.72e-06	0.000114	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—NRG1—thyroid cancer	2.71e-06	0.000114	CbGpPWpGaD
Gefitinib—ABCB1—Transmembrane transport of small molecules—RXRA—thyroid cancer	2.7e-06	0.000114	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—CHST14—thyroid cancer	2.68e-06	0.000113	CbGpPWpGaD
Gefitinib—ERBB3—Disease—PTGS2—thyroid cancer	2.67e-06	0.000113	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—TPR—thyroid cancer	2.67e-06	0.000112	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	2.66e-06	0.000112	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—PRKAR1A—thyroid cancer	2.63e-06	0.000111	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—SST—thyroid cancer	2.6e-06	0.000109	CbGpPWpGaD
Gefitinib—EGFR—Disease—NRG1—thyroid cancer	2.59e-06	0.000109	CbGpPWpGaD
Gefitinib—MKNK1—Disease—HRAS—thyroid cancer	2.57e-06	0.000108	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—PTEN—thyroid cancer	2.53e-06	0.000106	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—TPR—thyroid cancer	2.52e-06	0.000106	CbGpPWpGaD
Gefitinib—EGFR—Axon guidance—HRAS—thyroid cancer	2.5e-06	0.000105	CbGpPWpGaD
Gefitinib—ERBB3—Innate Immune System—AKT1—thyroid cancer	2.5e-06	0.000105	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CALCA—thyroid cancer	2.5e-06	0.000105	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—PRKAR1A—thyroid cancer	2.48e-06	0.000104	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—NRAS—thyroid cancer	2.46e-06	0.000103	CbGpPWpGaD
Gefitinib—EGFR—Signaling by NGF—AKT1—thyroid cancer	2.44e-06	0.000103	CbGpPWpGaD
Gefitinib—EGFR—Developmental Biology—NRAS—thyroid cancer	2.44e-06	0.000103	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—TERT—thyroid cancer	2.44e-06	0.000103	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—KRAS—thyroid cancer	2.43e-06	0.000102	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—PTEN—thyroid cancer	2.41e-06	0.000102	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—BRAF—thyroid cancer	2.41e-06	0.000101	CbGpPWpGaD
Gefitinib—ERBB3—Adaptive Immune System—AKT1—thyroid cancer	2.4e-06	0.000101	CbGpPWpGaD
Gefitinib—IRAK1—Innate Immune System—HRAS—thyroid cancer	2.36e-06	9.92e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Disease—KRAS—thyroid cancer	2.35e-06	9.89e-05	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—RXRA—thyroid cancer	2.34e-06	9.86e-05	CbGpPWpGaD
Gefitinib—ERBB3—Disease—PTEN—thyroid cancer	2.33e-06	9.82e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—HIF1A—thyroid cancer	2.33e-06	9.81e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—TERT—thyroid cancer	2.33e-06	9.79e-05	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—PTEN—thyroid cancer	2.32e-06	9.76e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—BRAF—thyroid cancer	2.32e-06	9.76e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—TPR—thyroid cancer	2.3e-06	9.68e-05	CbGpPWpGaD
Gefitinib—MKNK1—Disease—AKT1—thyroid cancer	2.27e-06	9.55e-05	CbGpPWpGaD
Gefitinib—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—thyroid cancer	2.27e-06	9.54e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—PRKAR1A—thyroid cancer	2.26e-06	9.52e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CDK1—thyroid cancer	2.26e-06	9.52e-05	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—NRAS—thyroid cancer	2.25e-06	9.48e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	2.25e-06	9.46e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—HIF1A—thyroid cancer	2.23e-06	9.37e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—CCND1—thyroid cancer	2.22e-06	9.35e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—HPGD—thyroid cancer	2.16e-06	9.09e-05	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—NRAS—thyroid cancer	2.15e-06	9.07e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—PTEN—thyroid cancer	2.14e-06	9.02e-05	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—KRAS—thyroid cancer	2.12e-06	8.91e-05	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—PTEN—thyroid cancer	2.1e-06	8.85e-05	CbGpPWpGaD
Gefitinib—EGFR—Developmental Biology—KRAS—thyroid cancer	2.1e-06	8.83e-05	CbGpPWpGaD
Gefitinib—IRAK1—Innate Immune System—AKT1—thyroid cancer	2.08e-06	8.76e-05	CbGpPWpGaD
Gefitinib—ERBB3—Disease—NRAS—thyroid cancer	2.08e-06	8.76e-05	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—NRAS—thyroid cancer	2.07e-06	8.71e-05	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—HRAS—thyroid cancer	2.07e-06	8.7e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—TPR—thyroid cancer	2.06e-06	8.69e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	2.05e-06	8.63e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—PRKAR1A—thyroid cancer	2.03e-06	8.55e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—TPR—thyroid cancer	2.01e-06	8.48e-05	CbGpPWpGaD
Gefitinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—thyroid cancer	2.01e-06	8.48e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—SLC5A5—thyroid cancer	2e-06	8.41e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Disease—HRAS—thyroid cancer	2e-06	8.41e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—PRKAR1A—thyroid cancer	1.98e-06	8.34e-05	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—KRAS—thyroid cancer	1.94e-06	8.16e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—BRAF—thyroid cancer	1.93e-06	8.12e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—NRAS—thyroid cancer	1.91e-06	8.05e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—TPR—thyroid cancer	1.9e-06	7.99e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—SLC5A5—thyroid cancer	1.89e-06	7.95e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—TPR—thyroid cancer	1.88e-06	7.92e-05	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—TP53—thyroid cancer	1.88e-06	7.92e-05	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—NRAS—thyroid cancer	1.88e-06	7.9e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—PRKAR1A—thyroid cancer	1.87e-06	7.86e-05	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—KRAS—thyroid cancer	1.85e-06	7.8e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—PRKAR1A—thyroid cancer	1.85e-06	7.79e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—BRAF—thyroid cancer	1.84e-06	7.76e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	1.84e-06	7.75e-05	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—AKT1—thyroid cancer	1.83e-06	7.68e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—NRG1—thyroid cancer	1.81e-06	7.64e-05	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—HRAS—thyroid cancer	1.8e-06	7.57e-05	CbGpPWpGaD
Gefitinib—ERBB3—Disease—KRAS—thyroid cancer	1.79e-06	7.54e-05	CbGpPWpGaD
Gefitinib—EGFR—Developmental Biology—HRAS—thyroid cancer	1.78e-06	7.51e-05	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—KRAS—thyroid cancer	1.78e-06	7.49e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	1.77e-06	7.45e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Disease—AKT1—thyroid cancer	1.76e-06	7.42e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—CCND1—thyroid cancer	1.76e-06	7.39e-05	CbGpPWpGaD
Gefitinib—ALB—Platelet activation, signaling and aggregation—AKT1—thyroid cancer	1.73e-06	7.27e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—SLC5A5—thyroid cancer	1.72e-06	7.24e-05	CbGpPWpGaD
Gefitinib—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—thyroid cancer	1.7e-06	7.16e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—PTEN—thyroid cancer	1.69e-06	7.13e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—CCND1—thyroid cancer	1.69e-06	7.12e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—RXRA—thyroid cancer	1.68e-06	7.07e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	1.68e-06	7.06e-05	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—HRAS—thyroid cancer	1.65e-06	6.94e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—KRAS—thyroid cancer	1.65e-06	6.93e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—PTEN—thyroid cancer	1.63e-06	6.87e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—TERT—thyroid cancer	1.63e-06	6.86e-05	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—KRAS—thyroid cancer	1.61e-06	6.8e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	1.61e-06	6.79e-05	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—AKT1—thyroid cancer	1.59e-06	6.68e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—RXRA—thyroid cancer	1.59e-06	6.68e-05	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—HRAS—thyroid cancer	1.58e-06	6.63e-05	CbGpPWpGaD
Gefitinib—EGFR—Developmental Biology—AKT1—thyroid cancer	1.58e-06	6.63e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—HIF1A—thyroid cancer	1.56e-06	6.56e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—SLC5A5—thyroid cancer	1.54e-06	6.5e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	1.54e-06	6.49e-05	CbGpPWpGaD
Gefitinib—ERBB3—Disease—HRAS—thyroid cancer	1.52e-06	6.41e-05	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—HRAS—thyroid cancer	1.51e-06	6.37e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—NRAS—thyroid cancer	1.51e-06	6.36e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—SLC5A5—thyroid cancer	1.51e-06	6.35e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—PTGS2—thyroid cancer	1.49e-06	6.27e-05	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—PPARG—thyroid cancer	1.48e-06	6.23e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—TP53—thyroid cancer	1.46e-06	6.16e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—NRAS—thyroid cancer	1.46e-06	6.13e-05	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—AKT1—thyroid cancer	1.46e-06	6.13e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	1.45e-06	6.09e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—RXRA—thyroid cancer	1.45e-06	6.09e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—SLC5A5—thyroid cancer	1.42e-06	5.98e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—SLC5A5—thyroid cancer	1.41e-06	5.93e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—CCND1—thyroid cancer	1.41e-06	5.93e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	1.41e-06	5.92e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—PTEN—thyroid cancer	1.41e-06	5.92e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—HRAS—thyroid cancer	1.4e-06	5.89e-05	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—AKT1—thyroid cancer	1.39e-06	5.86e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—NRAS—thyroid cancer	1.38e-06	5.8e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—NRAS—thyroid cancer	1.37e-06	5.78e-05	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—HRAS—thyroid cancer	1.37e-06	5.78e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—PTEN—thyroid cancer	1.36e-06	5.72e-05	CbGpPWpGaD
Gefitinib—ERBB3—Disease—AKT1—thyroid cancer	1.34e-06	5.66e-05	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—AKT1—thyroid cancer	1.34e-06	5.62e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	1.32e-06	5.56e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—KRAS—thyroid cancer	1.3e-06	5.48e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—PTEN—thyroid cancer	1.3e-06	5.46e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—RXRA—thyroid cancer	1.3e-06	5.46e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—BRAF—thyroid cancer	1.29e-06	5.43e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—RXRA—thyroid cancer	1.27e-06	5.33e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	1.26e-06	5.31e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—NRAS—thyroid cancer	1.25e-06	5.28e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—KRAS—thyroid cancer	1.25e-06	5.28e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—TPR—thyroid cancer	1.24e-06	5.22e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—AKT1—thyroid cancer	1.24e-06	5.2e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—PRKAR1A—thyroid cancer	1.22e-06	5.14e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—NRAS—thyroid cancer	1.21e-06	5.11e-05	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—AKT1—thyroid cancer	1.21e-06	5.1e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—RXRA—thyroid cancer	1.19e-06	5.02e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—KRAS—thyroid cancer	1.19e-06	4.99e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—RXRA—thyroid cancer	1.18e-06	4.98e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—KRAS—thyroid cancer	1.18e-06	4.97e-05	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—PTGS2—thyroid cancer	1.16e-06	4.9e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—NRAS—thyroid cancer	1.16e-06	4.87e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—TP53—thyroid cancer	1.16e-06	4.87e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	1.15e-06	4.85e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—TP53—thyroid cancer	1.11e-06	4.69e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—HRAS—thyroid cancer	1.11e-06	4.65e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—KRAS—thyroid cancer	1.08e-06	4.54e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—HRAS—thyroid cancer	1.07e-06	4.49e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—PPARG—thyroid cancer	1.06e-06	4.46e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—TP53—thyroid cancer	1.05e-06	4.44e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—KRAS—thyroid cancer	1.04e-06	4.39e-05	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—PTEN—thyroid cancer	1.02e-06	4.27e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—HRAS—thyroid cancer	1.01e-06	4.24e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—HRAS—thyroid cancer	1e-06	4.23e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—PPARG—thyroid cancer	1e-06	4.22e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—KRAS—thyroid cancer	9.97e-07	4.2e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—AKT1—thyroid cancer	9.76e-07	4.11e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CCND1—thyroid cancer	9.42e-07	3.96e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—AKT1—thyroid cancer	9.41e-07	3.96e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—SLC5A5—thyroid cancer	9.29e-07	3.91e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—TP53—thyroid cancer	9.28e-07	3.91e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—HRAS—thyroid cancer	9.18e-07	3.86e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—PPARG—thyroid cancer	9.13e-07	3.84e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—PTEN—thyroid cancer	9.09e-07	3.83e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—AKT1—thyroid cancer	8.9e-07	3.75e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—HRAS—thyroid cancer	8.87e-07	3.73e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—AKT1—thyroid cancer	8.87e-07	3.73e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—HRAS—thyroid cancer	8.47e-07	3.57e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—PTGS2—thyroid cancer	8.34e-07	3.51e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—PPARG—thyroid cancer	8.2e-07	3.45e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—NRAS—thyroid cancer	8.11e-07	3.41e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—AKT1—thyroid cancer	8.1e-07	3.41e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—PPARG—thyroid cancer	8e-07	3.37e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—PTGS2—thyroid cancer	7.88e-07	3.32e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—AKT1—thyroid cancer	7.84e-07	3.3e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—RXRA—thyroid cancer	7.81e-07	3.29e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—PPARG—thyroid cancer	7.54e-07	3.17e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—AKT1—thyroid cancer	7.48e-07	3.15e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—PPARG—thyroid cancer	7.47e-07	3.15e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—PTEN—thyroid cancer	7.27e-07	3.06e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—PTGS2—thyroid cancer	7.18e-07	3.02e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—KRAS—thyroid cancer	6.98e-07	2.94e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—PTEN—thyroid cancer	6.87e-07	2.89e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—PTGS2—thyroid cancer	6.45e-07	2.71e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—PTGS2—thyroid cancer	6.29e-07	2.65e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—PTEN—thyroid cancer	6.26e-07	2.64e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—TP53—thyroid cancer	6.2e-07	2.61e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—HRAS—thyroid cancer	5.93e-07	2.5e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—PTGS2—thyroid cancer	5.93e-07	2.5e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—PTGS2—thyroid cancer	5.88e-07	2.47e-05	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—AKT1—thyroid cancer	5.85e-07	2.46e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—PTEN—thyroid cancer	5.62e-07	2.37e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—PTEN—thyroid cancer	5.49e-07	2.31e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—AKT1—thyroid cancer	5.24e-07	2.21e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—PTEN—thyroid cancer	5.17e-07	2.18e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—PTEN—thyroid cancer	5.13e-07	2.16e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—PPARG—thyroid cancer	4.93e-07	2.07e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—AKT1—thyroid cancer	4.19e-07	1.76e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—AKT1—thyroid cancer	3.96e-07	1.67e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—PTGS2—thyroid cancer	3.88e-07	1.63e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—AKT1—thyroid cancer	3.61e-07	1.52e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—PTEN—thyroid cancer	3.38e-07	1.42e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—AKT1—thyroid cancer	3.24e-07	1.36e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—AKT1—thyroid cancer	3.16e-07	1.33e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—AKT1—thyroid cancer	2.98e-07	1.25e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—AKT1—thyroid cancer	2.95e-07	1.24e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—AKT1—thyroid cancer	1.95e-07	8.2e-06	CbGpPWpGaD
